- Home
- BEEM vs SABS Comparison
BEEM vs SABS Comparison
Compare BEEM & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEEM
- SABS
- Stock Information
- Founded
- BEEM 2006
- SABS 2014
- Country
- BEEM United States
- SABS United States
- Employees
- BEEM N/A
- SABS N/A
- Industry
- BEEM Semiconductors
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- BEEM Technology
- SABS Health Care
- Exchange
- BEEM Nasdaq
- SABS Nasdaq
- Market Cap
- BEEM 31.9M
- SABS 31.2M
- IPO Year
- BEEM N/A
- SABS N/A
- Fundamental
- Price
- BEEM $1.82
- SABS $4.09
- Analyst Decision
- BEEM Strong Buy
- SABS Strong Buy
- Analyst Count
- BEEM 3
- SABS 3
- Target Price
- BEEM $4.00
- SABS $9.00
- AVG Volume (30 Days)
- BEEM 559.8K
- SABS 206.2K
- Earning Date
- BEEM 11-14-2025
- SABS 11-13-2025
- Dividend Yield
- BEEM N/A
- SABS N/A
- EPS Growth
- BEEM N/A
- SABS N/A
- EPS
- BEEM N/A
- SABS N/A
- Revenue
- BEEM $27,668,000.00
- SABS $114,698.00
- Revenue This Year
- BEEM N/A
- SABS N/A
- Revenue Next Year
- BEEM $45.38
- SABS N/A
- P/E Ratio
- BEEM N/A
- SABS N/A
- Revenue Growth
- BEEM N/A
- SABS N/A
- 52 Week Low
- BEEM $1.33
- SABS $1.00
- 52 Week High
- BEEM $4.23
- SABS $6.60
- Technical
- Relative Strength Index (RSI)
- BEEM 34.68
- SABS 71.11
- Support Level
- BEEM $1.64
- SABS $3.68
- Resistance Level
- BEEM $1.76
- SABS $4.15
- Average True Range (ATR)
- BEEM 0.18
- SABS 0.31
- MACD
- BEEM -0.00
- SABS 0.04
- Stochastic Oscillator
- BEEM 24.91
- SABS 93.18
About BEEM Beam Global
Beam Global produces sustainable technology for electric vehicle (EV) charging, outdoor media, and energy security, without the construction, disruption, and costs of grid-tied solutions. Its products are founded upon its patented EV ARC and Solar Treelines and include BeamTrak patented solar tracking, and ARC Technology energy storage, along with EV charging, outdoor media, and disaster preparedness packages. From start to finish, the company develops, patents, designs, engineers, and manufactures renewably energized products that help the environment, empower communities, and keep people moving.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.